Cargando…

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma

Glioblastoma is the most common and aggressive primary tumor of the central nervous system with poor outcome. Current gold standard treatment is surgical resection followed by a combination of radio- and chemotherapy. Efficacy of temozolomide (TMZ), the primary chemotherapeutic agent, depends on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xinyu, Abdallah, Mohammed O.E., Breuer, Peter, Stahl, Fabian, Bakhit, Yousuf, Potthoff, Anna-Laura, Pregler, Barbara E.F., Schneider, Matthias, Waha, Andreas, Wüllner, Ullrich, Evert, Bernd O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475512/ https://www.ncbi.nlm.nih.gov/pubmed/37634280 http://dx.doi.org/10.1016/j.neo.2023.100929

Ejemplares similares

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
por: Rahman, Mohummad Aminur, et al.
Publicado: (2019)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas, Reena P, et al.
Publicado: (2012)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation
por: Wu, Moli, et al.
Publicado: (2023)

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide
por: Potthoff, Anna-Laura, et al.
Publicado: (2019)

Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression
por: Li, Qiang, et al.
Publicado: (2020)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
por: Tancredi, Alessandro, et al.
Publicado: (2022)

Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of MGMT and BCL-XL
por: Tang, Jun-Hai, et al.
Publicado: (2017)

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
por: Dunn, J, et al.
Publicado: (2009)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status
por: Wu, Qiong, et al.
Publicado: (2023)

Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen
por: Stahl, Fabian, et al.
Publicado: (2021)

Use Of Temozolomide In Parathyroid Carcinoma With Negative Mgmt Promoter Methylation
por: Reddy, Niyoti, et al.
Publicado: (2021)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
por: Melguizo, Consolación, et al.
Publicado: (2012)

Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status
por: Schneider, Matthias, et al.
Publicado: (2021)

Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
por: Egaña, Larraitz, et al.
Publicado: (2020)

On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
por: Stepanenko, Aleksei A., et al.
Publicado: (2019)

Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated MGMT
por: Álvarez-Torres, María del Mar, et al.
Publicado: (2021)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
por: Wang, Ke, et al.
Publicado: (2017)

Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma
por: Struve, Nina, et al.
Publicado: (2020)

PLA2G6 ‐associated late‐onset parkinsonism in a Sudanese family
por: Bakhit, Yousuf, et al.
Publicado: (2023)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
por: Perazzoli, Gloria, et al.
Publicado: (2015)

Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2
por: Yi, Guo-zhong, et al.
Publicado: (2019)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression
por: Persano, L, et al.
Publicado: (2012)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
por: Nie, Er, et al.
Publicado: (2018)

Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
por: Alnahhas, Iyad, et al.
Publicado: (2020)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
por: Nie, Er, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ol980i5iotbf8bir8nh2fmpsmh